Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma

Craig B. Reeder, Donna E. Reece, Vishal Kukreti, Christine Chen, Suzanne Trudel, Kristina Laumann, Joseph Hentz, Nicholas A. Pirooz, Jesus G. Piza, Rodger Tiedemann, Joseph R. Mikhael, Peter L. Bergsagel, Jose F. Leis, Rafael Fonseca, Alexander K. Stewart

Blood (2010) 115 (16): 3416–3417.

https://doi.org/10.1182/blood-2010-02-271676

Published: 2010

Journal Articles

Pharmacogenomics (PGx) Research in the APEX Randomized Multicenter International Phase 3 Trial Comparing Bortezomib and High-Dose Dexamethasone (Dex).

G. Mulligan, C. Mitsiades, B. Bryant, F. Zhan, W. Cheng, S. Eschrich, B. Burrington, P. Richardson, W. Trepicchio, J. Shaughnessy, L. Bergsagel, A. Damokosh, A. Boral, D. Esseltine, D. Schenkein, K. Anderson

Blood (2005) 106 (11): 3491.

https://doi.org/10.1182/blood.V106.11.3491.3491

Published: 2005

Journal Articles

Depsipeptide in the Treatment of Relapsed and Refractory Multiple Myeloma (MM): A Prospective Evaluation of the Cell Cycle.

Zoe Goldberg*, MD, Scott Ely, MD, Selina Chen-Kiang, PhD, Martha Chesi, PhD, Peter L. Bergsagel, MD, Karen Pekle*, RN, Larry Lyons*, Udi Gelbshtein*, Roger Pearse, MD, PhD, John Harpel, MD, PhD, Hearn Cho, MD, PhD, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2004) 104 (11): 1497.

https://doi.org/10.1182/blood.V104.11.1497.1497

Published: 2004

Journal Articles

Ectopic Fibroblast Growth Factor Receptor 3 (FGFR3) Expression Mediated by Isotype Switch Recombination.

Maurizio Affer, Phd, Davide Robbiani, MD, Marta Chesi, Phd, Peter L. Bergsagel, MD

Blood (2004) 104 (11): 78.

https://doi.org/10.1182/blood.V104.11.78.78

Published: 2004

Journal Articles

Dysregulation of MMSET Is Tumorigenic In-Vivo.

Marta Chesi, PhD, Kruti Naik, MSc, Davide F. Robbiani, MD, Maurizio Affer, PhD, Helen D. Nickerson, PhD, Peter L. Bergsagel, MD

Blood (2004) 104 (11): 74.

https://doi.org/10.1182/blood.V104.11.74.74

Published: 2004

NARROW

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma

Pharmacogenomics (PGx) Research in the APEX Randomized Multicenter International Phase 3 Trial Comparing Bortezomib and High-Dose Dexamethasone (Dex).

Depsipeptide in the Treatment of Relapsed and Refractory Multiple Myeloma (MM): A Prospective Evaluation of the Cell Cycle.

Ectopic Fibroblast Growth Factor Receptor 3 (FGFR3) Expression Mediated by Isotype Switch Recombination.

Dysregulation of MMSET Is Tumorigenic In-Vivo.

Email alerts

ASH Publications

American Society of Hematology

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma

Pharmacogenomics (PGx) Research in the APEX Randomized Multicenter International Phase 3 Trial Comparing Bortezomib and High-Dose Dexamethasone (Dex).

Depsipeptide in the Treatment of Relapsed and Refractory Multiple Myeloma (MM): A Prospective Evaluation of the Cell Cycle.

Ectopic Fibroblast Growth Factor Receptor 3 (FGFR3) Expression Mediated by Isotype Switch Recombination.

Dysregulation of MMSET Is Tumorigenic In-Vivo.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only